| Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore |
Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this is through the Relative Strength Index (RSI), a technical momentum indicator that signals when a stock may be due for a rebound. |
marketbeat.com |
2025-05-14 12:30:32 |
Czytaj oryginał (ang.) |
| Krystal Biotech to Present at BofA Securities 2025 Health Care Conference |
PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day. |
globenewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript |
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Stephane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - SVP, Patient Access, Analytics and Operations Christine Wilson - SVP and Head, U.S. Sales and Marketing Kate Romano - CAO Conference Call Participants Alec Stranahan - Bank of America Roger Song - Jefferies Ritu Baral - TD Cowen Gavin Clark-Gartner - Evercore ISI Sami Corwin - William Blair Andrea Newkirk - Goldman Sachs Debjit Chattopadhyay - Guggenheim Securities Yigal Nochomovitz - Citigroup Operator Thank you for standing by, and welcome to the Krystal Biotech First Quarter 2025 Earnings Call. At this time, all participants are on a listen-only mode. |
seekingalpha.com |
2025-05-06 18:43:13 |
Czytaj oryginał (ang.) |
| Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down |
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down. |
zacks.com |
2025-05-06 18:40:37 |
Czytaj oryginał (ang.) |
| Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates |
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.20 per share, missing the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $0.03 per share a year ago. |
zacks.com |
2025-05-06 14:15:38 |
Czytaj oryginał (ang.) |
| Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? |
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-29 15:06:09 |
Czytaj oryginał (ang.) |
| Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa |
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. VYJUVEK is designed to address the genetic root cause of DEB by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing. |
globenewswire.com |
2025-04-28 11:00:00 |
Czytaj oryginał (ang.) |
| Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer |
PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth has also served as a valuable contributor on Jeune's board of directors since February 2021. |
globenewswire.com |
2025-04-07 20:30:00 |
Czytaj oryginał (ang.) |
| 5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 |
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector. |
zacks.com |
2025-04-07 18:25:39 |
Czytaj oryginał (ang.) |
| Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK |
Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation, potentially boosting its global market presence and valuation. Despite KRYS's premium valuation, its growth potential, strong financials, and first-mover advantage justify the market's appraisal, with a fair value estimate of $175-$185 per share. Key risks include regulatory setbacks, reimbursement issues, competition from Abeona's EB-101, and high operational expenses, which could impact short-term valuation and cash flow. |
seekingalpha.com |
2025-03-24 10:30:00 |
Czytaj oryginał (ang.) |
| Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue? |
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-03-21 14:36:28 |
Czytaj oryginał (ang.) |
| Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-03-17 12:50:25 |
Czytaj oryginał (ang.) |
| Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait? |
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth. |
zacks.com |
2025-03-08 06:40:29 |
Czytaj oryginał (ang.) |
| Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait? |
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth. |
zacks.com |
2025-03-08 06:35:30 |
Czytaj oryginał (ang.) |
| KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug |
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU. |
zacks.com |
2025-03-03 14:01:10 |
Czytaj oryginał (ang.) |
| Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa |
PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's) announcement that its Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the European Commission (EC) to approve VYJUVEK® (beremagene geperpavec-svdt, or B-VEC) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. The CHMP's positive opinion includes support for administration of VYJUVEK in either a health care setting (e.g. |
globenewswire.com |
2025-02-28 09:40:00 |
Czytaj oryginał (ang.) |
| Why Krystal Biotech (KRYS) Might be Well Poised for a Surge |
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2025-02-24 15:20:24 |
Czytaj oryginał (ang.) |
| Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-24 12:55:37 |
Czytaj oryginał (ang.) |
| Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know |
Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-02-21 15:00:34 |
Czytaj oryginał (ang.) |
| Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus |
Krystal Biotech's VYJUVEK shows strong growth, with 2025 sales expected to exceed $1B, bolstered by launches in the EU and Japan. Q4 earnings beat EPS expectations but slightly missed revenue forecasts; however, management's 2025 outlook coming catalysts drove a strong rally in shares. Key 2025 catalysts include VYJUVEK's EU and Japan launches, Phase 3 ocular DEB results, and progress in CF and lung gene therapy. |
seekingalpha.com |
2025-02-21 10:15:00 |
Czytaj oryginał (ang.) |
| Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up |
KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake. |
zacks.com |
2025-02-20 11:55:28 |
Czytaj oryginał (ang.) |
| Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript |
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q4 2024 Results Conference Call February 19, 2025 8:30 AM ET Company Participants Stephane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Jennifer McDonough - SVP, Patient Access, Analytics and Operations Christine Wilson - SVP and Head, U.S. Sales and Marketing Suma Krishnan - President, Research and Development Kate Romano - CAO Conference Call Participants Alec Stranahan - BOA Ritu Baral - TD Cowen Gavin Clark-Gartner - Evercore ISI Sami Corwin - William Blair Ry Forseth - Guggenheim Josh Schimmer - Cantor Andrea Newkirk - Goldman Sachs Operator Thank you for standing by, and welcome to the Krystal Biotech Q4 2024 Earnings Call. At this time, all participants are on a listen-only mode. |
seekingalpha.com |
2025-02-19 13:43:02 |
Czytaj oryginał (ang.) |
| Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results |
Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023 |
globenewswire.com |
2025-02-19 09:00:00 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Krystal Biotech (KRYS) Stock? |
Investors need to pay close attention to Krystal Biotech (KRYS) stock based on the movements in the options market lately. |
zacks.com |
2025-01-24 12:41:44 |
Czytaj oryginał (ang.) |
| Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer |
PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Director in Evercore's healthcare group, where he advised on transactions totaling over $500 billion in aggregate value. |
globenewswire.com |
2025-01-14 10:00:00 |
Czytaj oryginał (ang.) |
| Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy |
Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales, doubling from Q4 2023. Trading at 57x 2024 earnings, Krystal's stock appears expensive but is projected to double earnings by 2025. With imminent EU and Japanese market expansion, Krystal seems poised to outperform analyst's expectations for growth. |
seekingalpha.com |
2024-12-27 10:30:00 |
Czytaj oryginał (ang.) |
| KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707 |
Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707. |
zacks.com |
2024-12-19 14:11:16 |
Czytaj oryginał (ang.) |
| Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer |
Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today initial clinical results from its ongoing KYANITE-1 study evaluating inhaled KB707 in patients with solid tumors of the lung. KB707 administered via inhalation demonstrated early evidence of monotherapy activity that was most pronounced in patients with advanced non-small cell lung cancer (NSCLC), where an objective response rate (ORR) of 27% and disease control rate (DCR) of 73% were observed as of data cut-off on December 6, 2024. |
globenewswire.com |
2024-12-18 10:00:00 |
Czytaj oryginał (ang.) |
| KRYS Stock Down on Initial Clinical Updates on KB407 & KB408 |
Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases. |
zacks.com |
2024-12-13 14:11:08 |
Czytaj oryginał (ang.) |
| Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa |
CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) cancelled the Oral Explanation regarding the Company's Marketing Authorization Application for beremagene geperpavec-svdt (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) that was scheduled for December 6, 2024, and asked the Company to submit written responses to the remaining outstanding issues. |
globenewswire.com |
2024-12-09 18:15:00 |
Czytaj oryginał (ang.) |
| Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report? |
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-04 14:36:40 |
Czytaj oryginał (ang.) |
| Krystal Biotech to Present at Upcoming Investor Conferences |
PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences: |
globenewswire.com |
2024-11-27 09:00:00 |
Czytaj oryginał (ang.) |
| Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference |
PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day. |
globenewswire.com |
2024-11-06 09:00:00 |
Czytaj oryginał (ang.) |
| Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction |
KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake. |
zacks.com |
2024-11-05 17:01:11 |
Czytaj oryginał (ang.) |
| Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript |
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Stéphane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - SVP, Patient Access, Analytics and Operations Christine Wilson - SVP and Head, U.S. Sales and Marketing Kate Romano - CAO Conference Call Participants Alec Stranahan - BOA Yigal Nochomovitz - Citigroup Ritu Baral - TD Cowen Sami Corwin - William Blair Gavin Clark-Gartner - Evercore ISI Dae Gon Ha - Stifel Debjit Chattopadhyay - Guggenheim Securities Andrea Newkirk - Goldman Sachs Operator Thank you for standing by and welcome to Krystal Biotech's Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. |
seekingalpha.com |
2024-11-04 17:31:30 |
Czytaj oryginał (ang.) |
| Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates |
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to loss of $0.67 per share a year ago. |
zacks.com |
2024-11-04 12:10:19 |
Czytaj oryginał (ang.) |
| Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth |
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-28 13:05:30 |
Czytaj oryginał (ang.) |
| Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024 |
PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets. |
globenewswire.com |
2024-10-28 09:00:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy |
Krystal Biotech (KRYS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-10-18 17:00:35 |
Czytaj oryginał (ang.) |
| Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On |
The company anticipates significant Q4 2024 data releases for KB707 in solid tumors and KB408 in AATD lung disease, potentially boosting shareholder value. Jeune Therapeutics, a subsidiary, shows promise in aesthetics with positive phase 1 data, changing the treatment paradigm in the aesthetics market space. VYJUVEK, approved for DEB, saw a 55.3% revenue increase in Q2 2024, with potential European expansion pending MAA approval. |
seekingalpha.com |
2024-10-14 20:58:31 |
Czytaj oryginał (ang.) |
| Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference |
PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the 2024 Cantor Global Healthcare Conference on September 18, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:20 pm ET and host investor meetings throughout the day. |
globenewswire.com |
2024-09-13 11:00:00 |
Czytaj oryginał (ang.) |
| Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference |
PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a company presentation at 12:30 pm ET and host investor meetings throughout the day. |
globenewswire.com |
2024-09-06 11:00:00 |
Czytaj oryginał (ang.) |
| Surging Earnings Estimates Signal Upside for Krystal Biotech (KRYS) Stock |
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2024-09-03 17:21:49 |
Czytaj oryginał (ang.) |
| Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow? |
KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress. |
zacks.com |
2024-08-30 18:31:17 |
Czytaj oryginał (ang.) |
| Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript |
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q2 2024 Earnings Conference Call August 5, 2024 8:30 AM ET Company Participants Stéphane Paquette - Vice President, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - Senior Vice President, Patient Access, Analytics and Operations Christine Wilson - Senior Vice President and Head, U.S. Sales and Marketing Kate Romano - Chief Accounting Officer Conference Call Participants Alec Stranahan - Bank of America Ritu Baral - TD Cowen Andrea Tan - Goldman Sachs John Boyle - William Blair Yigal Nochomovitz - Citi Gavin Clark Gartner - Evercore ISI Dae Gon Ha - Stifel Debjit Chattopadhyay - Guggenheim Securities Operator Thank you for standing by. And welcome to Krystal Biotech's Second-Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-08-10 00:10:29 |
Czytaj oryginał (ang.) |